Crossref
The GLP-1 Medication Safety Gap: Why Every New Obesity Prescription Should Trigger a Pharmacotherapy Review
International Journal of Clinical Pharmacy and Medicine · 16.11.2026
DOI: 10.68760/s2026146 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Pharmacy and Medicine, online erschienen am 16.11.2026. Verfasst von Sarah Jenkins und 1 weiteren Autor:innen.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Jenkins, S., & Hunter, M. (2026). The GLP-1 Medication Safety Gap: Why Every New Obesity Prescription Should Trigger a Pharmacotherapy Review. International Journal of Clinical Pharmacy and Medicine. https://doi.org/10.68760/s2026146
Vancouver
Jenkins S, Hunter M. The GLP-1 Medication Safety Gap: Why Every New Obesity Prescription Should Trigger a Pharmacotherapy Review. International Journal of Clinical Pharmacy and Medicine. 2026. doi:10.68760/s2026146
BibTeX
@article{Jenkins2026,
author = {Jenkins, Sarah and Hunter, Michael},
title = {The GLP-1 Medication Safety Gap: Why Every New Obesity Prescription Should Trigger a Pharmacotherapy Review},
journal = {International Journal of Clinical Pharmacy and Medicine},
year = {2026},
doi = {10.68760/s2026146}
}
EUVIMED